We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
Cap. Flow
-$430M
Cap. Flow %
-8.52%
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22
Avg Time Held Equity + Options
7.7 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
7.5 quarters
Avg Time Held Equity only
8 quarters
Top 10 Avg Time Held Equity only
5.7 quarters
Top 20 Avg Time Held Equity only
7.9 quarters

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$129M
2
MRK icon
Merck
MRK
+$76.6M
3
GH icon
Guardant Health
GH
+$43.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$31.5M
5
QURE icon
uniQure
QURE
+$28.3M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$87M
2
LLY icon
Eli Lilly
LLY
+$65.3M
3
APLS icon
Apellis Pharmaceuticals
APLS
+$61M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.8M
5
CI icon
Cigna
CI
+$56.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Miscellaneous 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RPTX icon
126
DELISTED
Repare Therapeutics
RPTX
– –
-3,322,488
Closed -$8.64M –
TARS icon
127
Tarsus Pharmaceuticals
TARS
$3.31B
– –
-154,400
Closed -$12.6M –
TERN icon
128
DELISTED
Terns Pharmaceuticals
TERN
– –
-2,153,300
Closed -$87M –
UTHR icon
129
United Therapeutics
UTHR
$23.4B
– –
-105,200
Closed -$51.3M –
VIR icon
130
Vir Biotechnology
VIR
$1.8B
– –
-2,380,715
Closed -$14.4M –
VTGN icon
131
CALL
VistaGen Therapeutics
VTGN
$9.5M
– –
-45,200
Closed -$29.9K –
MPLT icon
132
MapLight Therapeutics
MPLT
$442M
– –
-56,000
Closed -$952K –
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2026 Portfolio in Review

As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.

  • OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
  • OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
  • OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
  • OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
  • OrbiMed opened 26 new positions and closed 22 in Q1 2026.
  • OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.